9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 53

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: Has Results

Outcome Measures: Progression Free Survival Rate at 6 Months,  Response Rate,  Overall Survival,

Interventions: bevacizumab, cisplatin

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: June 2010

Completion Date: August 2010

Last  Posted Date: January 5, 2017

Location: University of Texas Southwestern Medical Center, Dallas, Texas, United States

Website Link: https://ClinicalTrials.gov/show/NCT00295503

Was this article helpful?
Dislike 0